Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorNunes, Maria Carmo
dc.contributor.authorBern, Caryn
dc.contributor.authorClark, Eva
dc.contributor.authorTeixeira, Antonio Lucio
dc.contributor.authorMolina Romero, Israel
dc.date.accessioned2024-11-26T11:37:20Z
dc.date.available2024-11-26T11:37:20Z
dc.date.issued2024-09
dc.identifier.citationNunes MCP, Bern C, Clark EH, Teixeira AL, Molina I. Clinical features of Chagas disease progression and severity. Lancet Reg Heal Am. 2024 Sep;37:100832.
dc.identifier.issn2667-193X
dc.identifier.urihttps://hdl.handle.net/11351/12277
dc.descriptionChagas cardiomyopathy; Chagas disease; Progression
dc.description.abstractChagas disease, the most common form of nonischaemic cardiomyopathy globally, is one of the leading causes of morbidity and mortality in Latin America. Chagas cardiomyopathy has a wide clinical spectrum and prognosis, which is primarily determined by the severity of left ventricular dysfunction. Chagas disease also affects the brain, particularly manifesting as cardioembolic strokes and cognitive impairments. Disease progression is influenced by various factors such as anti-parasite treatments, host–parasite interactions, and other determinants. This review explores Chagas disease, covering clinical presentations, the range of severity of Chagas cardiomyopathy, and neurological manifestations. We investigate factors that influence the progression of cardiomyopathy, including anti-parasitic treatments, interactions between hosts and parasites, and the influence of social determinants on the course of the disease. This review analyses key prognostic factors associated with the progression and mortality of Chagas cardiomyopathy, offering insights into this potentially fatal illness.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesThe Lancet Regional Health Americas;37
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectChagas, Malaltia de - Prognosi
dc.subjectMiocardi - Malalties - Prognosi
dc.subject.meshChagas Cardiomyopathy
dc.subject.meshChagas Disease
dc.subject.meshDisease Progression
dc.titleClinical features of Chagas disease progression and severity
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.lana.2024.100832
dc.subject.decsmiocardiopatía chagásica
dc.subject.decsenfermedad de Chagas
dc.subject.decsprogresión de la enfermedad
dc.relation.publishversionhttps://doi.org/10.1016/j.lana.2024.100832
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Nunes MCP] Hospital das Clínicas and Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. [Bern C] Department of Epidemiology and Biostatistics, University of California San Francisco School of Medicine, San Francisco, CA, USA. [Clark EH] Department of Medicine, Section of Infectious Diseases and Department of Pediatrics, Division of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA. [Teixeira AL] Faculdade Santa Casa BH, Belo Horizonte, MG, Brazil. The Biggs Institute, UT Health Science Center, San Antonio, TX, USA. [Molina I] Unitat de Medicina Tropical i Salut Internacional Drassanes, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid39474468
dc.identifier.wos001316791500001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record